Alterity Therapeutics Limited — Form 20-F Summary
Reporting period: Fiscal year ended June 30, 2019; filed August 30, 2019. This is an annual report, not a standalone 2018 Q4 filing, despite the request metadata. Financial statements are audited and prepared under IFRS in Australian dollars (A$), unless stated otherwise.
Business context
Alterity, formerly Prana Biotechnology, is a development-stage biotechnology company researching treatments for neurodegenerative diseases. Its lead candidate is PBT434, targeting Parkinsonian disorders, initially multiple system atrophy (MSA). The company has no commercial product revenue. Its ADSs began trading as ATHE on Nasdaq after the April 8, 2019 name change; each ADS represents 60 ordinary shares.
Financial performance and position
| Metric (A$ unless noted) | FY2019 | FY2018 |
|---|---|---|
| Commercial revenue | None reported | None reported |
| Interest income | 108,538 | 201,174 |
| Other income, primarily R&D tax incentive | 4,951,167 | 3,125,775 |
| Research and development expense | 12,983,185 | 6,698,016 |
| General and administrative expense | 4,308,352 | 4,341,058 |
| Net loss | (12,337,830) | (8,265,737) |
| Basic and diluted loss per share | (2.00) cents | (1.55) cents |
| Operating cash flow | (13,954,818) | (6,245,188) |
| Cash and cash equivalents at year-end | 14,399,904 | 15,235,556 |
| Working capital | 16,541,001 | 16,010,651 |
| Total assets | 19,909,918 | 18,726,013 |
| Total liabilities | 3,355,145 | 2,644,856 |
| Net assets | 16,554,773 | 16,081,157 |
R&D tax-incentive income is not product sales. The company recorded an A$4.83 million receivable for its FY2019 Australian R&D incentive claim, expected to be received within the following 12 months. The filing reports no borrowings; liabilities are principally payables and employee provisions. Profit margins are not meaningful for a pre-commercial company.
Material changes versus FY2018
- R&D expense rose 93.8%, primarily reflecting the PBT434 Phase 1 study and other research activity. The net loss widened by A$4.07 million.
- Operating cash outflow more than doubled, while year-end cash declined by A$0.84 million. Financing activities provided A$12.72 million, including equity issuance.
- Ordinary shares outstanding increased from 533.9 million to 860.8 million. The April 2019 Life Biosciences investment and related placements were major sources of financing.
- Life Biosciences invested approximately US$7.5 million and received 269.9 million shares plus warrants for 539.8 million shares. The warrants were exercisable at A$0.045 and expired December 19, 2019.
Outlook, developments and risks
- Management said available cash and other assets were expected to cover creditors and commitments and forecast cash outflows for at least 12 months from the report date. Directors intended to raise additional equity within 12 months; no financing commitment was disclosed. The company stated it could reduce or defer planned spending if funding were unavailable.
- PBT434 Phase 1 in healthy and elderly volunteers was reported completed in July 2019, after fiscal year-end. The company described the candidate as safe and well tolerated, with no serious adverse events, and said it had begun preparing further studies targeting MSA. FDA orphan-drug designation for PBT434 in MSA was granted in January 2019.
- PBT2 remains subject to an FDA partial clinical hold following neurotoxicity findings in a dog study. The filing says further characterization is needed and discusses possible additional toxicology, lower doses or alternative indications; no clear development decision or timetable is provided.
- The central risks are continued losses, substantial future financing needs and dilution, uncertain clinical and regulatory outcomes, and dependence on third-party research and manufacturing. Life Biosciences’ warrants and shareholding give it significant influence; the filing states its potential ownership could reach 57.81% on exercise.
- The filing reports no material legal proceedings or contingent liabilities. Research and development termination commitments were approximately A$2.3 million, generally subject to 30 days’ notice. Operating lease commitments totaled A$111,811.
- Management assessed disclosure controls and internal control over financial reporting as effective at June 30, 2019. The auditor issued an unqualified opinion on the IFRS financial statements but did not audit internal control effectiveness.
Important facts for investors to verify
- Confirm the latest cash balance, receipt of the A$4.83 million R&D tax incentive, subsequent financing, and actual cash runway.
- Check the post-year-end status and terms of the 539.8 million warrants, including exercise, expiry and resulting dilution; reconcile warrant totals elsewhere in the filing, which also cites 586.7 million warrants issued across investors.
- Review current PBT434 clinical plans and evidence beyond the Phase 1 volunteer study, and the regulatory path for MSA.
- Confirm the FDA partial-hold status and any updated development plan for PBT2.
- Reconcile cash-flow disclosures: the audited statement reports FY2019 operating outflow of A$13.95 million, while parts of the narrative cite approximately A$13.89 million. Also distinguish A$13.08 million of gross equity proceeds from A$12.72 million of net financing cash flow.
- Assess Life Biosciences’ voting influence, board representation and potential ownership after warrant exercise, alongside the company’s future financing and dilution requirements.